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o r i g i n a l a r t i c l e
Prediction of Recurrent Clostridium Difﬁcile Infection Using
Comprehensive Electronic Medical Records in an Integrated
Healthcare Delivery System
Gabriel J. Escobar, MD;1 Jennifer M. Baker, MPH, CHES;2 Patricia Kipnis, PhD;1,3 John D. Greene, MA;1
T. Christopher Mast, PhD, MSc;4 Swati B. Gupta, DrPH, MPH;5 Nicole Cossrow, MPH, PhD;4 Vinay Mehta, PhD;4
Vincent Liu, MD, MS;1,6 Erik R. Dubberke, MD7
background. Predicting recurrent Clostridium difﬁcile infection (rCDI) remains difﬁcult. METHODS. We employed a retrospective cohort
design. Granular electronic medical record (EMR) data had been collected from patients hospitalized at 21 Kaiser Permanente Northern
California hospitals. The derivation dataset (2007–2013) included data from 9,386 patients who experienced incident CDI (iCDI) and 1,311 who
experienced their ﬁrst CDI recurrences (rCDI). The validation dataset (2014) included data from 1,865 patients who experienced incident
CDI and 144 who experienced rCDI. Using multiple techniques, including machine learning, we evaluated more than 150 potential predictors.
Our ﬁnal analyses evaluated 3 models with varying degrees of complexity and 1 previously published model.
results. Despite having a large multicenter cohort and access to granular EMR data (eg, vital signs, and laboratory test results), none of the
models discriminated well (c statistics, 0.591–0.605), had good calibration, or had good explanatory power.
conclusions. Our ability to predict rCDI remains limited. Given currently available EMR technology, improvements in prediction will
require incorporating new variables because currently available data elements lack adequate explanatory power.
Infect Control Hosp Epidemiol 2017;38:1196–1203
Clostridium difﬁcile infection (CDI) is a serious illness whose
presentation can range from loose stools to profuse watery
diarrhea, leading to dehydration, life-threatening complica-
tions, and sometimes death. This illness is associated with
substantial morbidity, mortality, excess health services utiliza-
tion, and increased cost.1–3 The Centers for Disease Control
and prevention estimated that there were 453,000 cases of
incident CDI (iCDI) in 2011, with 29,000 associated deaths
and 83,000 ﬁrst recurrences (rCDI).1 Recurrences are com-
mon due to persistent or newly acquired bacterial spores.4
After initial treatment and resolution of diarrhea, up to 35% of
CDI patients experience rCDI.1,5,6 Of those with a primary
recurrence, 40% will have another CDI episode, and after 2
recurrences, the likelihood of an additional episode increases
to as high as 65%.7 However, due to recent advances, this
estimate may be overstated.8,9
Prevention of rCDI remains a critical unmet medical need,
and it is desirable to predict which patients are at highest risk
of recurrence. A number of research teams have developed
predictive models for rCDI.10–13 These models have had lim-
ited sample size, have been restricted to data from a single
center, have employed imprecise proxies for measures of dis-
ease severity, and have made limited use of electronic medical
record (EMR) data.
A need exists for risk prediction models to address these
gaps. As more healthcare systems in the United States transi-
tion to fully automated EMRs, it is important to take advantage
of the increased granular clinical data that are becoming
available. Although health systems are beginning to experi-
ment with predictive models embedded in EMRs,14–16 access
to such capability remains limited. The overall incidence of
CDI is affected by local factors such as antimicrobial stew-
ardship efforts, patient case mix, varying antibiotic utilization
patterns, C. difﬁcile strain epidemiology, and prevention. Thus,
models may not be completely generalizable and may need
periodic updating. Although considerable interest in predict-
ing rCDI exists, descriptions of the performance characteristics
of existing models have been limited, and few have been
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sufﬁciently validated outside the populations in which they
were developed. Now that treatments are available to prevent
the recurrence of CDI (eg, ﬁdaxomicin,17,18 bezlotoxumab19),
it is advantageous to patients and healthcare providers to
identify those at greatest risk for recurrence who may beneﬁt
from the most appropriate treatments.
To address these gaps, we developed and validated rCDI pre-
dictive models in a large and representative sample of adults. For
our deﬁned population, cared for by a single medical group within
an integrated delivery system, Kaiser Permanente Northern
California (KPNC), comprehensive EMR data were available. Our
modeling process included comparing different models and
externally validating a previously published model.
materials and methods
This project was approved by the KPNC Institutional Review
Board for the Protection of Human Subjects, which has jurisdic-
tion over all the hospitals and clinics described in this report.
Our setting consisted of 21 KPNC hospitals described pre-
viously.20–22 Under a mutual exclusivity arrangement, salaried
physicians of The Permanente Medical Group care for 4.2 million
Kaiser Foundation Health Plan members at facilities owned by
Kaiser Foundation Hospitals. All KPNC facilities (21 hospitals and
an additional 60 clinics) employ the same information systems
with a commonmedical record number.23 Comprehensive KPNC
information systems permit tracking of patient information across
the continuum of care, including some aspects of care outside
KPNC.22,23 Deployment of the Epic EMR system (www.epicsys-
tems.com), known internally as KP HealthConnect (KPHC),
began in 2006 and was completed in 2010.
The eligible population (denominator) included adults ≥18
years of age with at least 1 positive test (the index test) for
C. difﬁcile toxins or DNA associated with a hospitalization
between 2007 and 2014. The date-time stamp of the physician
order for the index test was time zero (T0) for all study mea-
surements. Details on KPNC assays and testing procedures are
provided in the Appendix.
Measures
Primary study outcome. The dependent variable was rCDI,
which could occur either in the inpatient or outpatient setting.
To ensure that we distinguished between incident and
recurrent episodes, T0 had to be preceded by an 84-day
period with no evidence of CDI (Figure 1). A patient’s
treatment period extended from the ﬁrst known instance of
antibiotic treatment to 48 hours after conclusion of such
treatment. A positive test deﬁning a patient as having rCDI had
to occur within 84 days after the end of the treatment period.
Tests that occurred within the treatment period were not
included. Figure 1 also shows that predictors were included if
available up to 4 days after T0, a clinically reasonable period for
acquisition of information following a CDI testing order.
Mortality. We ascertained mortality using KPNC patient
demographic databases and publicly available ﬁles of deceased
patients provided by the Social Security Administration, as
described previously.22
Model development. We assessed more than 150 potential
predictors, including age, sex, and different conﬁgurations
of historical variables (eg, antibiotic exposure, recent hos-
pitalizations, and surgery). The ﬁnal set of 23 predictors
incorporated in the 3 models was based on clinical grounds,
statistical performance, data abstraction burden in settings
without EMRs, and (for the fully automated models) current
KPNC data availability.15,16
Predictors fell into the following categories: demographic
(age, sex), location of iCDI onset (either the inpatient setting or a
skilled nursing facility), medication exposure (antibiotics, proton
pump inhibitors), comorbidities (both as individual predictors as
well as composite indices such as the Charlson comorbidity
index24 and the 12-month longitudinal COmorbidity Point
Score, version 2, or COPS222), medical history (eg, recent surgery
involving the gastrointestinal tract), and physiologic markers
(ie, laboratory tests, vital signs, and a severity of illness score, the
Laboratory-based Acute Physiology Score, version 2 (LAPS2).22
The LAPS2 employs 16 laboratory tests, vital signs, pulse oximetry,
and neurological status checks. We categorized 24 antibiotics as
ﬁgure 1. Time periods employed to deﬁne patient inclusion in cohort and patient data in predictive models. The T0 is deﬁned by the
date/time stamp of the physician order for the index test. In order for the patient to be included in the cohort, the T0 had to be preceded by
84 days with no positive test for Clostridium difﬁcile (“clean” period). To be considered an outcome, an infection had to occur during
the Recurrence period. This meant that a positive test result occurred within 84 days following the end of a variable treatment period
(time between the T0 and completion of antibiotic treatment, ABXEND). Patient data included in the predictive models had to be available
within 4 days from the T0 (Predictor period). See text for additional details.
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high risk (eg, ciproﬂoxacin, clindamycin, and amoxicillin).25–27
A full list of the predictors examined is provided in the Appendix.
Based on statistical performance, the 3 best-performing
models are described here: basic, enhanced, and automated.
The basic model is a parsimonious model with components
that could be easily populated in most medical settings.
The enhanced model is a variant of the basic model to which
a limited set of variables, which could be extracted from an
EMR, were added. These variables, which are part of the
LAPS2 severity of illness score,22 were based on their statistical
contribution using methods described below. Finally, the
automated model is based on variables that could be generated
in real time given existing systems in place in KPNC.16
We elected to compare these ﬁnal 3 models against the
Zilberberg model, a previously published model by Zilberberg
et al,25 because it was based on a large cohort and the authors
provided substantive detail on its statistical performance. For the
Zilberberg model, we structured predictors to match the speci-
ﬁcations of Zilberberg et al exactly. However, we did not employ
their original coefﬁcients, instead allowing these to emerge given
table 1. Predictors Used Within Each Model
Modela
Predictor Basic Zilberbergb Enhanced Automated
Age (continuous) x x
Age (splines) x
Gastrointestinal surgery within 30 d prior to T0 x x
Immunosuppression statusc x x
Locus of iCDI onsetd x x x
Admitted from a skilled nursing facility x x
≥ 2 hospitalizations within 60 d prior to T0 x
New gastric acid suppression (PPI) at the onset of iCDI x
High-risk antibiotic at the onset of iCDIe x
Fluoroquinolone at the onset of iCDI x
Patient in the ICU at the onset of iCDI x
Blood urea nitrogen x
Creatinine x




Total white blood cell count x
Lowest temperature within T0 + 4 d x x
Highest temperature within T0 + 4 d x x
LAPS2+ splinesf x
COPS2+ splinesg x
Elapsed hospital length of stay at T0 x
NOTE. LAPS2, laboratory-based acute physiology score, version 2; COPS, comorbidity point score, version 2; T0, Time
zero (T0) is the date-time stamp of the physician order for the index Clostridium difﬁcile infection test; iCDI, incident
Clostridium difﬁcile infection (see text for how iCDI is deﬁned); ICU, intensive care unit.
aSee text for more detail on model selection.
bWe replicated the model developed by Zilberberg et al.25
cA patient’s immunosuppression status was deﬁned using algorithmic rules using International Classiﬁcation of
Disease, Ninth Revision (ICD-9) diagnosis codes and immunocompromising medications and treatments used in the
6 mo prior to iCDI.
dLocus of iCDI onset is categorized as (1) community-onset, healthcare-facility–associated (iCDI diagnosed by a
positive toxin test within 72 h of admission or iCDI diagnosed in any outpatient setting and a hospitalization in the
prior 90 d); (2) community-onset, community-associated (reference group in model: iCDI diagnosed by a positive
toxin test within 72 h of admission or in any outpatient setting and no hospitalization in the previous 90 d); or (3)
hospital-onset, healthcare-facility–associated (CDI diagnosed > 72 h after hospital admission). These deﬁnitions
were also used by Zilberberg et al.25
eWe employed the same deﬁnitions as Zilberberg et al.25
fLAPS2 is a composite severity of illness score and employs 16 laboratory tests, vital signs, pulse oximetry, and
neurological status checks.22
gCOPS2 is a 12-month longitudinal comorbidity burden score that includes history elements (eg, recent surgery
involving the gastrointestinal track).22
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our population. The 4 models, arranged according to increasing
complexity, are summarized in Table 1.
Statistical Methods
We divided cohort data into derivation (patients with iCDI
between 2007 and 2013) and validation (iCDI in 2014) datasets.
All analyses during model development were performed using
the derivation dataset, with ﬁnal coefﬁcients applied once to the
validation dataset. As a further precaution against overﬁtting, we
divided derivation data into Derivation 1 (iCDI dates 2007–2012)
and Derivation 2 (2013) datasets.28 Within the Derivation 1
dataset, we identiﬁed a set of candidate predictors by ﬁrst per-
forming univariate and bivariate analyses and then applying a
random forest algorithm.28,29 We evaluated the performance and
robustness of all models on the Derivation 2 data set using 5-fold
cross-validation.30 We excluded multiple models because,
although they performed well in the derivation dataset, perfor-
mance deteriorated dramatically following cross-validation. This
was particularly true with respect to models that incorporated
multiple interaction terms.
We ﬁt a simple logistic regression, excluding deaths prior
to rCDI for the basic, the enhanced, and the automated
models. However, because patients with CDI have a substantial
mortality risk and might die prior to developing rCDI, we eval-
uated several models (based on the enhancedmodel predictors) to
address the possible impact ofmortality on rCDI prediction. These
included competing risk discrete survival models29 and Cox
competing risk survival regression.31 We conducted sensitivity
analyses in which we ﬁrst assigned a probability of rCDI
to all patients in a randomly selected portion of the derivation
dataset. We then tested various models using the remaining
records in which the dependent variable was not dichotomous
but continuous (ie, patients who died were assigned a probability
of rCDI, and then we modeled for rCDI as a continuous
outcome), and we incorporated the conditional probability of
mortality into the analyses. Additional details are provided in the
Appendix.
We compared the discrimination of each model using
the c statistic (area under the receiver operator characteristic
curve),32 calibration through calibration plots,33 the incremental
contribution of additional predictors using integrated discrimina-
tion improvement (IDI), and net reclassiﬁcation improvement as
recommended byCook34 and Pencina et al.35 As recommended by
Cook,34 we also included the Nagelkerke pseudo-R2 in our
assessments of model performance. In standard linear regression
models, the ratio of the mean-squared error to the variance of the
dependent variable can be subtracted from 1 to deﬁne an R2 that is
always between 0 and 1. In a validation sample, however, the
mean-squared error may exceed the variance of the dependent
variable, and the resulting R2 may be negative. A negative R2
indicates a very poor ﬁt with the validation sample.36
We also conducted sensitivity analyses in which we
employed a 30-day (as opposed to an 84-day) period for
outcome ascertainment.
results
We scanned KPNC databases from 2007 to 2014 and identiﬁed
a total of 41,499 positive tests for Clostridium difﬁcile. A total of
11,251 patients who experienced iCDI. In the derivation
dataset, a total of 9,386 patients with iCDI experienced 1,311
ﬁrst recurrences (14.0%); 2,197 (23.4%) patients died prior to
the end of the follow-up period; and 260 (2.8%) died following
a recurrence. The corresponding numbers in the validation
dataset were 1,865 iCDIs, 144 (7.7%) rCDIs, 376 (20.2%)
deaths prior to the end of the follow-up period, and 27 (1.4%)
deaths following rCDI. The Appendix provides a ﬂow chart
describing the cohort assembly. Excluding patients who died
prior to the end of the follow-up period, Table 2 summarizes
our cohort characteristics, which are fairly similar to the
cohort described by Zilberberg et al.25 However, in general, the
KPNC cohort was older but healthier (eg, the proportion with
Charlson scores <3 was 80%, while that in the Zilberberg et al
cohort was ~55%). Furthermore, the KPNC cohort generally
had lower risk (eg, only 24% were receiving high-risk anti-
biotics, compared to 40% in the Zilberberg cohort). Expanded
versions of this table are provided in the Appendix.
We compared performance of the discrete time survival
and competing risk Cox regression models against the simple
logistic regression algorithm where we excluded patients who
died prior to an rCDI. The simple logistic regression basic,
enhanced, and automated models showed performance com-
parable to that of the competing risk survival models.
Table 3 summarizes performance characteristics of our
models in the validation dataset. All models demonstrated
modest discrimination, as shown by their areas under the
receiver-operator characteristic curve, or c statistics (range,
0.591–0.605) and poor explanatory power, with negative
Nagelkerke pseudo-R2s (−0.1033 to −0.0875). At a predicted
risk of ≥15% the positive predictive value ranged from 11.0%
to 12.1%; sensitivity ranged from 69.4% to 79.2%; and speci-
ﬁcity ranged from 32.0% to 43.6% across the models. With
this threshold, the number of patients needed to evaluate
(NNE) to detect 1 case of rCDI ranged from 8.3 to 9.0 across
the models. Figure 2 shows calibration of the Zilberberg model
and the enhanced model; neither model was well calibrated.
Sensitivity analyses of the possible impact of mortality
indicate that consideration of this issue (eg, by assigning a
weighted probability of rCDI to patients who died and then
modeling for rCDI as a continuous outcome) did not improve
prediction. Sensitivity analyses using a 30-day (instead of 84-
day) follow-up period resulted in worse model performance.
Additional results are provided in the Appendix.
discussion
Using a large recent cohort, we developed and validated 3 rCDI
predictive models using contemporary modeling techniques
and EMR data. We also validated a previously published
model25 in a different population. However, despite including
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table 2. Incident Clostridium difﬁcile (iCDI) Cohort Description
Recurrencea No Recurrencea Total
No. 1,455 7,223 8,678 P Value
Age, median y (mean± standard deviation) 74.0 (71.3± 15.4) 69.0 (66.8± 17.2) 70.0 (67.5± 17.0) <.0001
Female, No. (%) 831 (57.1) 4,131 (57.2) 4,962 (57.2) .9557
Non-white race, No. (%) 351 (24.1) 2,068 (28.6) 2,419 (27.9) .0005
Charlson scoreb
0–2, No. (%) 1,141 (78.4) 5,817 (80.5) 6,958 (80.2) .0413
3–5, No. (%) 308 (21.2) 1,394 (19.3) 1,702 (19.6)
6 + , No. (%) 6 (0.4) 12 (0.2) 18 (0.2)
Community onset, community associated, No. (%)c 315 (21.6) 2,244 (31.1) 2,559 (29.5) <.0001
Community onset, healthcare-facility associated, No. (%)c 766 (52.6) 2,804 (38.8) 3,570 (41.1) <.0001
Hospital onset, healthcare-facility associated, No. (%)c 374 (25.7) 2,175 (30.1) 2,549 (29.4) .0008
No. of inpatient stays in 60 d preceding iCDI
0, No. (%) 581 (39.9) 3,953 (54.7) 4,534 (52.2) <.0001
1, No. (%) 603 (41.4) 2,252 (31.2) 2,855 (32.9)
2 + , No. (%) 271 (18.6) 1,018 (14.1) 1,289 (14.9)
Patient in intensive care at iCDI onset, No. (%) 121 (8.3) 853 (11.8) 974 (11.2) .0005
Any antibioticse at iCDI onset, No. (%) 610 (41.9) 3,170 (43.9) 3,780 (43.6) .1682
High-risk antibioticse at iCDI onset, No. (%) 351 (24.1) 1,764 (24.4) 2,115 (24.4) .8090
Fluoroquinolone at iCDI onset, No. (%) 168 (11.5) 687 (9.5) 855 (9.9) .0175
Low-risk antibioticsd at iCDI onset, No. (%) 127 (8.7) 835 (11.6) 962 (11.1) .0017
Intravenous vancomycin at iCDI onset, No. (%) 47 (3.2) 166 (2.3) 213 (2.5) .0361
LAPS2e at iCDI onset (mean± standard deviation) 75.0 (80.8± 43.4) 76.0 (81.7± 45.3) 76.0 (81.6± 45.0) .4591
COPS2e at iCDI onset (mean± standard deviation) 58.0 (69.0± 54.0) 45.0 (60.0± 52.6) 48.0 (61.5± 52.9) <.0001
Admitted from skilled nursing facility, No. (%) 260 (17.9) 843 (11.7) 1,103 (12.7) <.0001
NOTE. iCDI, incident Clostridium difﬁcile infection; LAPS2, laboratory-based acute physiology score, version 2; COPS2, comorbidity point score,
version 2.
aCohort consists of patients with iCDI. Patients who died during the follow-up period were removed from analysis.
bSee Deyo et al24 for details on how this score was assigned.
cLocus of iCDI onset is categorized as (1) community onset, healthcare-facility associated (iCDI diagnosed by a positive toxin test within 72 h
of admission or iCDI diagnosed in any outpatient setting and a hospitalization in the prior 90 d); (2) community onset, community associated
(reference group in model: iCDI diagnosed by a positive toxin test within 72 h of admission or in any outpatient setting and no hospitalization in
the previous 90 d); or (3) hospital onset, healthcare-facility associated (CDI diagnosed >72 h after hospital admission). These deﬁnitions were
also used by Zilberberg et al.25
dWe employed the same antibiotic classiﬁcations as Zilberberg et al.25
eFor an extended deﬁnition of LAPS2 and (COPS2), refer to the text and Escobar et al.22 For both of these scores, increasing values are associated
with increasing mortality risk. The univariate relationship of an admission LAPS2 with 30-d mortality is as follows: 0–59, 1.0%; 60–109, 5.0%,
110 + , 13.7%; the univariate relationship of COPS2 with 30-d mortality is as follows: 0–39, 1.7%; 40–64, 5.2%, 65 + , 9.0%.
table 3. Model Performance in the Validation Dataseta at a Predicted Risk of ≥15%
Modelb,c c Statistic R2 Brier Score Sensitivity Speciﬁcity PPV NPV NNE NRI IDI
Age ≥65 years 0.546 −0.1131 0.0944 67.36 41.86 11.04 92.30 9.06 … …
Basic model 0.591 −0.0910 0.0937 75.69 41.19 12.11 94.06 8.26 0.0766 0.011
Zilberberg model 0.591 −0.0875 0.0933 74.31 39.03 11.54 93.42 8.66 0.0412 0.011
Enhanced model 0.587 −0.0924 0.0936 69.44 43.64 11.66 93.03 8.58 0.0387 0.014
Automated model 0.605 −0.1033 0.0942 79.17 32.04 11.09 93.49 9.02 0.0199 0.012
NOTE. c statistic, area under the receiver operator characteristic curve; R2, Nagelkerke’s pseudo-R2; PPV, positive predictive value; NPV, negative
predictive value; NNE, number of incident cases one would need to evaluate to detect one recurrence; NRI, net reclassiﬁcation improvement;
IDI, integrated discrimination improvement; iCDI, incident Clostridium difﬁcile infection.
aThe validation dataset consisted of 1,865 iCDI patients, of whom 144 developed rCDI. A total of 376 iCDI patients died (and thus could not be
assessed for recurrence).
bSee text for description of the 4 models. “Age ≥65 years” refers to a simple decision rule based on age alone. Sensitivity, PPV, NPV, NNE, NRI,
and IDI are based on the model giving a predicted recurrence risk of ≥15% within 84 days.
cWe conducted sensitivity analyses using predicted risk of ≥20%, ≥25%, and ≥30%. These results are provided in the Appendix.
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highly granular EMR data (eg, vital signs, laboratory tests,
composite severity of illness scores, and longitudinal comor-
bidity), the models and underlying data had poor ability to
predict rCDI. We formally tested a common assumption made
by many investigators (ie, that deaths can simply be excluded
from the numerator). We found that this approach is justiﬁed,
and that including patients who die prior to the conclusion of
the follow-up period did not improve prediction. Lastly, we
found that shortening the length of follow-up to 30 days
resulted in worse model performance.
Some authors have reported better model performance.
Examination of these other studies paints a less optimistic
picture. Hu et al10 report the use of machine-learning appro-
aches and a c statistic of 0.80 in their validation dataset. How-
ever, this study had a very small sample size (N= 110, with
N = 64 in the validation dataset) and did not employ cross-
validation (ie, no formal assessment of the possibility that model
performance in a different population might be poor). We were
able to achieve c statistics that were this high in our derivation
dataset, but these apparently successful models demonstrated
considerable instability during cross-validation. We did not
pursue them further and chose more parsimonious models.
Contrary to previous literature reports, some predictors (eg,
speciﬁc antibiotic exposures) were of limited value, particu-
larly in models that included severity of illness. This probably
reﬂects the fact that severity of illness is highly correlated (and
may, in fact, be the underlying risk factor) with other pre-
dictors (eg, intensive care and antibiotics known to predispose
for CDI). We deliberately focused on predicting rCDI in iCDI
cases, though previous CDI is a well-known risk factor for
recurrence. It is possible that, had we included prior CDI as a
predictor, we might have achieved better model performance.
However, models that included the COPS2 score (a long-
itudinal comorbidity measure that captures information from
the preceding 12 months) did not perform much better.
Multiple investigators, using a variety of statistical approa-
ches, including machine-learning methods, have been unable
to produce static models with better performance using the
currently available set of predictors. While it is true that many
predictors reach statistical signiﬁcance in bivariate analyses
(particularly when the sample size is large), the clinical sig-
niﬁcance may be muted because the relative proportions of
patients with and without recurrence are not that different.
Further, it is clear that the risk factors (age, antibiotic expo-
sure, severity of illness) that place an individual at risk for iCDI
are also risk factors for rCDI. Thus, future efforts ought to be
placed on identifying better predictors rather than on using
different statistical approaches with the currently available
predictors. New predictors may include newer biomarkers (eg,
indicators of underlying predisposition to recurrence), environ-
mental factors (eg, proximity to other CDI patients, presence
of C. difﬁcile spores4), behavioral aspects (eg, handwashing),
and/ormolecular markers (eg, information on speciﬁc C. difﬁcile
strains). It is also important to consider rCDI in an ecological
context, and future predictive models may need to be explicit
about including environmental and ecological predictors
ﬁgure 2. Model Calibration Using the Validation Dataset. For both plots, the X axis shows predicted rates of recurrent CDI in 5%
increments, while the Y axis shows the actual observed rates (with associated 95% conﬁdence intervals) in the validation dataset for all
observations with that predicted level of risk. The dotted line shows what would be found were calibration to be perfect. For both the
Zilberberg and Enhanced models, calibration is poor: calibration fails at levels above 10% predicted risk. Observed rates do not approach
predicted rates, meaning that both models over-predict recurrent CDI. Additional calibration ﬁgures, including Hosmer-Lemeshow plots,
are provided in the Appendix.
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(eg, isolation rooms, who is roomed where, other family
members exposure), if such data become available.
One alternative that we did not explore because it is cur-
rently not feasible with existing EMRs, was to develop dynamic
models. In contrast to the static approach we and others have
employed (ie, providing a single probability estimate based on
a discrete set of predictors available at some T0), such models
adjust posterior probabilities based on new information. In the
case of rCDI, having additional information on both antibiotic
treatment as well as other exposures (eg, proton pump
inhibitors) could have dramatic effects on our ability to
predict recurrence.37,38 The development of such models
would require EMRs with greater capabilities than those
currently available.
Our study had several additional limitations. Due to
resource limitations and sparse data, we limited our cases to
inpatient iCDI. During this study, KPNC implemented
aggressive efforts to reduce CDI. As a result, our data show that
the incidences of iCDI and rCDI were decreasing in our study
cohort. Despite these limitations, models to predict recurrence
have value. They do permit identiﬁcation of patient subsets
with elevated or very low risk. In some scenarios, and in the
context of discrete interventions, the use of these models might
improve outcomes and decrease costs. In addition, existing
models point to predictors that can be assessed in the future,
such as the aforementioned ecological ones.
Compared to our ability to predict other outcomes (eg,
death, unplanned transfer to intensive care),16,20,22 our ability
to predict rCDI is limited and contrasts with much better
ability to predict iCDI.39,40 Given the major consequences of
rCDI on patient outcomes, our results support the need to
expand research on the prevention and treatment of recur-
rence. Such research may also result in the identiﬁcation of
novel predictors that are currently unavailable even in the
most comprehensive EMRs.
acknowledgments
This project was funded by a grant from Merck Sharp & Dohme Corporation,
Whitehouse Station, New Jersey. The authors wish to thank Juan Carlos
LaGuardia for help assembling the dataset, Dr Tracy Lieu for reviewing the
manuscript, Vanessa Rodriguez for formatting the text for publication, Anna
Cardellino for her assistance in drafting the protocol, and Mary Beth Dorr for
her review and guidance in the analysis.
Financial support: Dr Vincent Liu was funded by a National Institutes of
Health award (grant no. K23GM112018).
Potential conﬂicts of interest: The Kaiser Permanente authors Escobar, Kip-
nis, Liu, Greene, and Baker have no conﬂicts of interest to report. Dr Erik
Dubberke has received grant support from Rebiotix, Merck, and Sanoﬁ Pas-
teur; he also has consulting and advisory board relationships with Rebiotix,
Summit, GSK, Valenva, Sanoﬁ Pasteur. The remaining coauthors Cossrow,
Gupta, Mast, and Mehta are or were employees of Merck Sharp & Dohme
Corporation, a subsidiary of Merck & Co., Kenilworth, New Jersey, and
potentially own stock and/or hold stock options in the company.
Address correspondence to Gabriel J. Escobar, MD, Systems Research
Initiative, Kaiser Permanente Division of Research, 2000 Broadway Ave
(032 R01), Oakland, CA 94612-2304 (gabriel.escobar@kp.org) or John
Greene, MA, Systems Research Initiative, Kaiser Permanente
Northern California Division of Research, 2000 Broadway
Ave, Oakland, CA 94612 (john.d.greene@kp.org).
supplementary material
To view supplementary material for this article, please visit
https://doi.org/10.1017/ice.2017.176
references
1. Lessa FC, Winston LG, McDonald LC. Burden of Clostridium
difﬁcile infection in the United States. N Engl J Med 2015;372:
2369–2370.
2. Kwon JH, Olsen MA, Dubberke ER. The morbidity, mortality,
and costs associated with Clostridium difﬁcile infection. Infect Dis
Clin North Am 2015;29:123–134.
3. Olsen MA, Young-Xu Y, Stwalley D, et al. The burden of
Clostridium difﬁcile infection: estimates of the incidence of
CDI from US administrative databases. BMC Infect Dis 2016;
16:177.
4. Freedberg DE, Salmasian H, Cohen B, Abrams JA, Larson EL.
Receipt of antibiotics in hospitalized patients and risk for
Clostridium difﬁcile infection in subsequent patients who occupy
the same bed. JAMA Intern Med 2016;176:1801–1808.
5. McFarland LV. Renewed interest in a difﬁcult disease:
Clostridium difﬁcile infections—epidemiology and current treat-
ment strategies. Curr Opin Gastroenterol 2009;25:24–35.
6. Bouza E. Consequences of Clostridium difﬁcile infection: under-
standing the healthcare burden. Clin Microbiol Infect 2012;18
(Suppl 6):5–12.
7. McFarland LV, Elmer GW, Surawicz CM. Breaking the cycle:
treatment strategies for 163 cases of recurrent Clostridium difﬁcile
disease. Am J Gastroenterol 2002;97:1769–1775.
8. Zilberberg MD, Reske K, Olsen M, Yan Y, Dubberke ER. Risk
factors for recurrent Clostridium difﬁcile infection (CDI)
hospitalization among hospitalized patients with an initial
CDI episode: a retrospective cohort study. BMC Infect Dis 2014;
14:306.
9. Sheitoyan-Pesant C, Abou Chakra CN, Pepin J, Marcil-Heguy A,
Nault V, Valiquette L. Clinical and healthcare burden of multiple
recurrences of Clostridium difﬁcile infection. Clin Infect Dis
2016;62:574–580.
10. Hu MY, Katchar K, Kyne L, et al. Prospective derivation and
validation of a clinical prediction rule for recurrent Clostridium
difﬁcile infection. Gastroenterology 2009;136:1206–1214.
11. Eyre DW, Walker AS, Wyllie D, et al. Predictors of ﬁrst
recurrence of Clostridium difﬁcile infection: implications for
initial management. Clin Infect Dis 2012;55:S77–S87.
12. Hebert C, Du H, Peterson LR, Robicsek A. Electronic health
record–based detection of risk factors for Clostridium difﬁcile
infection relapse. Infect Control Hosp Epidemiol 2013;34:
407–414.
13. D’Agostino RB Sr., Collins SH, Pencina KM, Kean Y, Gorbach S.
Risk estimation for recurrent Clostridium difﬁcile infection based
on clinical factors. Clin Infect Dis 2014;58:1386–1393.
1202 infection control & hospital epidemiology october 2017, vol. 38, no. 10
14. Kollef MH, Chen Y, Heard K, et al. A randomized trial of
real-time automated clinical deterioration alerts sent to a rapid
response team. J Hosp Med 2014;9:424–429.
15. Escobar GJ, Dellinger RP. Early detection, prevention, and miti-
gation of critical illness outside intensive care settings. J Hosp Med
2016;11:S5–S10.
16. Escobar GJ, Turk BJ, Ragins A, et al. Piloting electronic medical
record-based early detection of inpatient deterioration in com-
munity hospitals. J Hosp Med 2016;11:S18–S24.
17. Watt M, Dinh A, Le Monnier A, Tilleul P. Cost-effectiveness
analysis on the use of ﬁdaxomicin and vancomycin to treat
Clostridium difﬁcile infection in France. J Med Econ 2017;20:
678–686.
18. Nelson RL, Suda KJ, Evans CT. Antibiotic treatment for
Clostridium difﬁcile–associated diarrhoea in adults. Cochrane
Database Syst Rev 2017;3:CD004610.
19. Wilcox MH, Gerding DN, Poxton IR, et al. Bezlotoxumab for
prevention of recurrent Clostridium difﬁcile infection. N Eng. J
Med 2017;376:305–317.
20. Escobar GJ, Greene JD, Gardner MN, Marelich GP, Quick B,
Kipnis P. Intra-hospital transfers to a higher level of care: con-
tribution to total hospital and intensive care unit (ICU) mortality
and length of stay (LOS). J Hosp Med 2011;6:74–80.
21. Liu V, Kipnis P, Rizk NW, Escobar GJ. Adverse outcomes asso-
ciated with delayed intensive care unit transfers in an integrated
healthcare system. J Hosp Med 2012;7:224–230.
22. Escobar GJ, Gardner MN, Greene JD, Draper D, Kipnis P. Risk-
adjusting hospital mortality using a comprehensive electronic
record in an integrated health care delivery system. Med Care
2013;51:446–453.
23. Selby JV. Linking automated databases for research in managed
care settings. Ann Intern Med 1997;127:719–724.
24. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity
index for use with ICD-9-CM administrative databases. J Clin
Epidemiol 1992;45:613–619.
25. Zilberberg MD, Reske K, Olsen M, Yan Y, Dubberke ER. Devel-
opment and validation of a recurrent Clostridium difﬁcile
risk-prediction model. J Hosp Med 2014;9:418–423.
26. Dubberke ER, Reske KA, Yan Y, Olsen MA, McDonald LC,
Fraser VJ. Clostridium difﬁcile–associated disease in a setting of
endemicity: identiﬁcation of novel risk factors.Clin Infect Dis 2007;45:
1543–1549.
27. Dubberke ER, Yan Y, Reske KA, et al. Development and valida-
tion of a Clostridium difﬁcile infection risk prediction model.
Infect Control Hosp Epidemiol 2011;32:360–366.
28. Hastie T, Tibshirani R, Friedman JH. The Elements of Statistical
Learning: Data Mining, Inference, and Prediction. 2nd ed.
New York: Springer Verlag; 2009.
29. Allison PD. Logistic Regression Using SAS: Theory and Application.
2nd ed. Cary, NC: SAS Institute; 2012.
30. Hastie T, Tibshirani R, Friedman J, Franklin J. The elements of
statistical learning: data mining, inference and prediction.
Mathemat Intelligenc 2005;27:83–85.
31. Hosmer DW, Lemeshow S. Applied Survival Analysis: Regression
Modelling of Time to Event Data. Hoboken, NJ: Wiley; 2008.
32. Cook DA, Duke G, Hart GK, Pilcher D, Mullany D. Review of the
application of risk-adjusted charts to analyse mortality outcomes
in critical care. Crit Care Resusc 2008;10:239–251.
33. Crowson CS, Atkinson EJ, Therneau TM. Assessing calibration of
prognostic risk scores. Stat Method Med Res 2014;25:1692–1706.
34. Cook NR. Use and misuse of the receiver operating characteristic
curve in risk prediction. Circulation 2007;115:928–935.
35. Pencina MJ, D’Agostino RB Sr, D’Agostino RB Jr, Vasan RS.
Evaluating the added predictive ability of a newmarker: from area
under the ROC curve to reclassiﬁcation and beyond. Stat Med
2008;27:157–172; discussion 207–212.
36. Estrella A, Mishkin FS. Predicting US recessions: ﬁnancial vari-
ables as leading indicators. Rev Econ Statist 1998;80:45–61.
37. McDonald EG, Milligan J, Frenette C, Lee TC. Continuous proton
pump inhibitor therapy and the associated risk of recurrent
Clostridium difﬁcile Infection. JAMA Intern Med 2015;175:784–791.
38. Deshpande A, Pasupuleti V, Thota P, et al. Risk factors for
recurrent Clostridium difﬁcile infection: a systematic review and
meta-analysis. Infect Control Hosp Epidemiol 2015;36:452–460.
39. Kuntz JL, Johnson ES, Raebel MA, et al. Predicting the risk of
Clostridium difﬁcile infection following an outpatient visit:
development and external validation of a pragmatic, prognostic
risk score. Clin Microbiol Infect 2015;21:256–262.
40. Kuntz JL, Smith DH, Petrik AF, et al. Predicting the risk of Clos-
tridium difﬁcile infection upon admission: a score to identify patients
for antimicrobial stewardship efforts. Perm J 2016;20:20–25.
predicting recurrent c. diff infection with emr data 1203
